- Home
- SAFT vs AUPH Comparison
SAFT vs AUPH Comparison
Compare SAFT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFT
- AUPH
- Stock Information
- Founded
- SAFT 1979
- AUPH 1993
- Country
- SAFT United States
- AUPH Canada
- Employees
- SAFT N/A
- AUPH N/A
- Industry
- SAFT Property-Casualty Insurers
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- SAFT Finance
- AUPH Health Care
- Exchange
- SAFT Nasdaq
- AUPH Nasdaq
- Market Cap
- SAFT 1.2B
- AUPH 999.8M
- IPO Year
- SAFT N/A
- AUPH 1999
- Fundamental
- Price
- SAFT $81.84
- AUPH $7.96
- Analyst Decision
- SAFT
- AUPH Strong Buy
- Analyst Count
- SAFT 0
- AUPH 2
- Target Price
- SAFT N/A
- AUPH $11.50
- AVG Volume (30 Days)
- SAFT 44.3K
- AUPH 1.3M
- Earning Date
- SAFT 05-07-2025
- AUPH 07-31-2025
- Dividend Yield
- SAFT 4.40%
- AUPH N/A
- EPS Growth
- SAFT 40.60
- AUPH N/A
- EPS
- SAFT 4.90
- AUPH 0.27
- Revenue
- SAFT $1,153,213,000.00
- AUPH $247,295,000.00
- Revenue This Year
- SAFT N/A
- AUPH $12.15
- Revenue Next Year
- SAFT N/A
- AUPH $18.31
- P/E Ratio
- SAFT $16.76
- AUPH $29.47
- Revenue Growth
- SAFT 17.03
- AUPH 29.20
- 52 Week Low
- SAFT $70.71
- AUPH $5.15
- 52 Week High
- SAFT $90.00
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- SAFT 56.01
- AUPH 46.96
- Support Level
- SAFT $80.11
- AUPH $7.77
- Resistance Level
- SAFT $83.77
- AUPH $8.58
- Average True Range (ATR)
- SAFT 1.72
- AUPH 0.31
- MACD
- SAFT -0.08
- AUPH -0.03
- Stochastic Oscillator
- SAFT 56.38
- AUPH 43.89
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.